Rituximab in the treatment of non-Hodgkin&rsquo;s lymphoma

Código QR

Rituximab in the treatment of non-Hodgkin&rsquo;s lymphoma

Beate Hauptrock, Georg HessHematology/Oncology, Johannes Gutenberg-University, Mainz, GermanyAbstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin&rsquo;s lymphoma (NHL). &nbsp;R...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beate Hauptrock, Georg Hess
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e9b43300eff141579113ef98d7a86425
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma
por: Armitage JO, et al.
Publicado: (2011)

mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report
por: Provencio M., et al.
Publicado: (2011)

Current advances in Hodgkin’s lymphoma
por: Joseph Vadakara, et al.
Publicado: (2019)

Antitumor activity of silver nanoparticles in Dalton&rsquo;s lymphoma ascites tumor model
por: Muthu Irulappan Sriram, et al.
Publicado: (2010)

Adalimumab for the treatment of Crohn&rsquo;s disease
por: Andrea Cassinotti, et al.
Publicado: (2008)

Natalizumab in the treatment of Crohn&rsquo;s disease
por: Danila Guagnozzi, et al.
Publicado: (2008)

Unusual presentation of a clinically isolated temporal region mass: Non‐Hodgkin lymphoma
por: Mariam Mella, et al.
Publicado: (2021)

MEDICAL TREATMENT IN HODGKIN LYMPHOMA
por: Nilgun Kurucu
Publicado: (2021)

Maintenance treatment with infliximab for the management of Crohn&rsquo;s disease in adults
por: Renato Caviglia, et al.
Publicado: (2009)

Massive pericardial effusion as the first manifestation of childhood non‐Hodgkin's lymphoma: A case report
por: Behzad Alizadeh, et al.
Publicado: (2021)

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
por: McKinney MS, et al.
Publicado: (2014)

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
por: Joseph M Tuscano, et al.
Publicado: (2009)

ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
por: Sanda Buruiana, et al.
Publicado: (2021)

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin&rsquo;s lymphoma and multiple myeloma
por: Louis M Pelus, et al.
Publicado: (2011)

Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin’s cell [Erratum]
por: Qu X, et al.
Publicado: (2013)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos T, et al.
Publicado: (2017)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF&alpha; blocker failure
por: Kekow J, et al.
Publicado: (2012)

Raoultella ornithinolytica in MALT-type non-Hodgkin Lymphoma
por: Rui Seixas, et al.
Publicado: (2021)

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
por: Song L, et al.
Publicado: (2019)

Association between Randall&rsquo;s plaque and calcifying nanoparticles
por: Neva &Ccedil;ift&ccedil;ioglu, et al.
Publicado: (2008)

Rituximab therapy in Greek patients with rheumatoid arthritis
por: Haralampos M Moutsopoulos, et al.
Publicado: (2008)

EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED HODGKIN’S LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT
por: Jhanzeb Iftikhar, et al.
Publicado: (2021)

Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin&#39;s cell
por: Qu X, et al.
Publicado: (2012)

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković B, et al.
Publicado: (2021)

Magnetic nanoformulation of azidothymidine 5&rsquo;-triphosphate for targeted delivery across the blood&ndash;brain barrier
por: Zainulabedin M Saiyed, et al.
Publicado: (2010)

Hodgkin's lymphoma
por: E. A. Demina, et al.
Publicado: (2020)

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013)

Proposal for Alzheimer&rsquo;s diagnosis using molecular buffer and bus network
por: Mitatha S, et al.
Publicado: (2011)

RESPONSE ASSESSMENT AND OUTCOMES IN PEDIATRIC B CELL NON-HODGKIN LYMPHOMA: OUR EXPERIENCE AT SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE
por: Palwasha Rehman, et al.
Publicado: (2020)

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
por: David Kaminetzky, et al.
Publicado: (2008)

Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
por: Hasan E, et al.
Publicado: (2012)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi&rsquo;s sarcoma
por: Francesca Cainelli, et al.
Publicado: (2009)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Chengxin Luo, et al.
Publicado: (2021)

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
por: Wiesik-Szewczyk E, et al.
Publicado: (2012)

Genetic Polymorphisms in NLRP3 Inflammasome-Associated Genes in Patients with B-Cell Non-Hodgkin’s Lymphoma
por: Liu ZH, et al.
Publicado: (2021)

Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by A&beta;1-42 in Alzheimer&rsquo;s disease models
por: Bernardi A, et al.
Publicado: (2012)

PROGNOSIS FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH PRIMARY INVOLVEMENT OF THE SPLEEN
por: Larisa Musteata, et al.
Publicado: (2021)

Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
por: Hongyan Ji, et al.
Publicado: (2021)

EPIDEMIOLOGY OF NON-HODGKIN’S LYMPHOMAS IN iRKUTSK REGION
por: E. V. Zubkova, et al.
Publicado: (2012)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
por: Re KA, et al.
Publicado: (2012)